Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: A systematic review of the evidence from microbiological and clinical studies

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 895-904

  Kelesidis, Theodoros ^a,b   Karageorgopoulos, Drosos E ^a   Kelesidis, Iosif ^a,c   Falagas, Matthew E ^a,b,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Citrobacter; Glycylcyclines; Imipenem; Klebsiella pneumoniae; Proteus; Serratia

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEMASE; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; POLYMYXIN B; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CITROBACTER; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; ENTEROBACTER; ENTEROBACTER INFECTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; HUMAN; KLEBSIELLA; MEDLINE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PROTEUS; REFERENCE VALUE; REVIEW; SERRATIA; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MINOCYCLINE; TREATMENT OUTCOME; UNITED STATES;

EID: 54549112250     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn311     Document Type: Review

References (83)

1. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: The dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29: 630-6.
2. Falagas ME, Rafailidis PI, Kofteridis D et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: A matched case-control study. J Antimicrob Chemother 2007; 60: 1124-30.
3. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14 413-20.
4. Kasiakou SK, Michalopoulos A, Soteriades ES et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-46.
5. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant Gram-negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008; 27: 439-43.
6. Vergidis PI, Falagas ME. Multidrug-resistant Gram-negative bacterial infections: The emerging threat and potential novel treatment options. Curr Opin Investig Drugs 2008; 9: 176-83.
7. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
8. Hoban DJ, Bouchillon SK, Johnson BM et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
9. Livermore DM. Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611-4.
10. Chopra I. Glycylcyclines: Third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001; 1: 464-9.
11. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49: 791-3.
12. Dean CR, Visalli MA, Projan SJ et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-8.
13. Visalli MA, Murphy E, Projan SJ et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-9.
14. Hawkey P, Finch R. Tigecycline: in vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 2007; 13 354-62.
15. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55: 1619-29.
16. Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
17. Woodford N, Hill RL, Livermore DM. In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 2007; 59: 582-3.
18. Souli M, Kontopidou FV, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50: 3166-9.
19. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn Microbiol Infect Dis 2001; 40: 173-7.
20. Ratnam I, Franklin C, Spelman DW. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram-negative bacteria from patients in the intensive care unit. Pathology 2007; 39: 586-8.
21. Pliatsika V, Afkou Z, Protonotariou E et al. In vitro activity of tigecycline against metallo-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2007; 60: 1406-7.
22. Castanheira M, Sader HS, Deshpande LM et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008; 52: 570-3.
23. Tan TY, Ng LS. Susceptibility of multi-resistant Gram-negative bacilli in Singapore to tigecycline as tested by agar dilution. Ann Acad Med Singapore 2007; 36: 807-10.
24. Morosini MI, Garcia-Castillo M, Coque TM et al. Antibiotic coresistance in extended-spectrum-β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2695-9.
25. Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: Molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56: 128-32.
26. Petersen PJ, Bradford PA. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 2005; 49: 3910-8.
27. Bouchillon SK, Hoban DJ, Johnson BM et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001-02. Diagn Microbiol Infect Dis 2005; 51: 291-5.
28. Bouchillon SK, Hoban DJ, Johnson BM et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005; 52 173-9.
29. Fritsche TR, Strabala PA, Sader HS et al. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005; 52: 209-13.
30. Fritsche TR, Sader HS, Stilwell MG et al. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections 2000-04. Diagn Microbiol Infect Dis 2005; 52: 195-201.
31. Ko KS, Song JH, Lee MY et al. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn Microbiol Infect Dis 2006; 55: 337-41.
32. Sorlozano A, Gutierrez J, Salmeron A et al. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum β-lactamase-producing Escherichia coli in Granada, Spain. Int J Antimicrob Agents 2006; 28: 532-6.
33. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50: 3479-84.
34. Hope R, Warner M, Potz NA et al. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006; 58: 1312-4.
35. Reinert RR, Low DE, Rossi F et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60: 1018-29.
36. Samra Z, Ofir O, Lishtzinsky Y et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007; 30: 525-9.
37. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55: 49-57.
38. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 2007; 57: 423-8.
39. Brown SID, Traczewski MM. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 2007; 45 2173-9.
40. Sotto A, Bouziges N, Jourdan N et al. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol (Paris) 2007; 55: 398-406.
41. DiPersio JR, Dowzicky MJ. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial. Int J Antimicrob Agents 2007; 29: 518-27.
42. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
43. Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400-4.
44. Reynolds R, Potz N, Colman M et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: The BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53: 1018-32.
45. Zhang YY, Zhou L, Zhu DM et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 2004; 50: 267-81.
46. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 Suppl 5: S315-32.
47. Sader HS, Jones RN, Dowzicky MJ et al. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit? Diagn Microbiol Infect Dis 2005; 52: 203-8.
48. Fritsche TR, Sader HS, Stilwell MG et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005; 52: 187-93.
49. Betriu C, Rodriguez-Avial I, Gomez M et al. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 2006; 56 437-44.
50. Kronvall G, Karlsson I, Walder M et al. Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation. J Antimicrob Chemother 2006; 57: 498-505.
51. Tuckman M, Petersen PJ, Howe AY et al. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Antimicrob Agents Chemother 2007; 51: 3205-11.
52. Curcio D, Fernandez F. Acinetobacter spp. susceptibility to tigecycline: A worldwide perspective. J Antimicrob Chemother 2007; 60: 449-50.
53. Sader HS, Mallick R, Kuznik A et al. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. Int J Antimicrob Agents 2007; 30: 514-20.
54. Hope R, Parsons T, Mushtaq S et al. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method. J Antimicrob Chemother 2007; 60: 770-4.
55. Seder HS, Jones RN, Stilwell MG et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52: 181-6.
56. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on tigecycline. Clin Microbiol Infect 2006; 12: 1147-9.
57. Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt) 2007; 8: 159-72.
58. Passarell JA, Meagher AK, Liolios K et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008; 52: 204-10.
59. Eagye KJ, Kuti JL, Dowzicky M et al. Empiric therapy for secondary peritonitis: A pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther 2007; 29 889-99.
60. Meagher AK, Passarell JA, Cirincione BB et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007; 51 1939-45.
61. Tigecycline 308 Study Group; Tigecycline 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline (TGC) with levofloxacin (LEV) in patients (pts) with community-acquired pneumonia (CAP) (abstract). In: Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 27-30 September 2006. American Society of Microbiology, L-1450, 2006.
62. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
63. Cobo J, Morosini MI, Pintado V et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008; 60: 319-22.
64. Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant Gram-negative bacteremias. J Chemother 2007; 19: 232-3.
65. Daly MW, Riddle DJ, Ledeboer NA et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007; 27: 1052-7.
66. Knueppel RC, Rahimian J. Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect Dis 2007; 45: 136-8.
67. Oliva ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
68. Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-70.
69. Souli M, Kontopidou FV, Papadomichelakis E et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek University Hospital. Clin Infect Dis 2008; 46: 847-54.
70. Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother 2007; 19: 753-4.
71. Krueger WA, Kempf VA, Peiffer M et al. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-β-lactamase-producing Escherichia coli. J Clin Microbiol 2008; 46: 817-20.
72. Martinez-Martinez L. Extended-spectrum β-lactamases and the permeability barrier. Clin Microbiol Infect 2008; 14 Suppl 1: 82-9.
73. Bolmstrom A, Karlsson A, Engelhardt A et al. Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J Clin Microbiol 2007; 45: 2474-9.
74. Hope R, Warner M, Mushtaq S et al. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines H2005. J Antimicrob Chemother 2005; 56: 1042-6.
75. van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 943-9.
76. Reid GE, Grim SA, Aldeza CA et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-201.
77. Schafer JJ, Goff DA, Stevenson KB et al. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27: 980-7.
78. Karageorgopoulos DE, Kelesidis T, Kelesidis I et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence. J Antimicrob Chemother 2008; 62: 45-55.
79. Keeney D, Ruzin A, McAleese F et al. MarA-mediated over-expression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008; 61: 46-53.
80. Keeney D, Ruzin A, Bradford PA. RamA a transcriptional regulator AcrAB an RND-type efflux pump are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 2007; 13: 1-6.
81. Conte JE Jr Golden JA, Kelly MG et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-9.
82. Scheetz MH, Qi C, Warren JR et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 1621-6.
83. Vouillamoz J, Moreillon P, Giddey M et al. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J Antimicrob Chemother 2008; 61: 371-4.